Search clinical trials for: CAR-T ineligible

Total 769 results

Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Hematological Malignancies

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

B-ALL

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Donor-derived CAR-T Cells in the Treatment of AML Patients

AML

China
The First Affiliated Hospital of Soochow University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Acute Myeloid Leukemia | Mixed Phenotype Acute Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Adicet Bio, Inc

Recruiting

A Phase 1 Study of ADI-001 in B Cell Malignancies (GLEAN-1)

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Shanxi Province Cancer Hospital
Shanghai Ultra-T Immune Therapeutics Co. LTD

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Acute Lymphocytic Leukemia， B-Cell

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
National Cancer Institute, Slovakia
Slovak Academy of Sciences

Recruiting

Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation (SCTMICROBIOM)

Hematologic Neoplasms

Slovakia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
Beijing Boren Hospital

Recruiting

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

Relapse/Recurrence | T-cell Leukemia/Lymphoma | Refractory T Lymphoblastic Leukemia/Lymphoma

China
University of Pennsylvania

Recruiting

huCART19-IL18 in NHL/CLL Patients

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-hodgkin Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Plasma Cell Tumors

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
University of Cologne
Janssen-Cilag G.m.b.H

Recruiting

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (GMMG-DADA)

Multiple Myeloma

Germany
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Steven Deeks
Caring Cross

Recruiting

CAR-T Cells for HIV Infection

HIV Infections

United States
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
University of Rochester

Recruiting

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Multiple Myeloma

United States
Fate Therapeutics

Recruiting

FT819 in Subjects With B-cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | Precursor B-Cell Acute Lymphoblastic Leukemia

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Adult B Acute Lymphoblastic Leukemia

China
Kim, Seok Jin
Celltrion; Samyang Biopharmaceuticals Corporation

Recruiting

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (Lemon-C)

Primary CNS Lymphoma

Korea, Republic of
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University

Recruiting

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Refractory Indolent Adult Non-Hodgkin Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Lymphoma | Leukemia

China
Nanfang Hospital of Southern Medical University

Recruiting

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia Not Having Achieved Remission

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
University of Texas Southwestern Medical Center

Recruiting

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

Non-Hodgkin Lymphoma

United States
University of Alabama at Birmingham

Not yet recruiting

Chemo-embolization for Head and Neck Cancer

Squamous Cell Carcinoma | SCCHN

United States
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

CD7+ Acute Leukemia | CD7+ Lymphoma

China
CARsgen Therapeutics Co., Ltd.
Fudan University; Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics

Recruiting

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Malignant Pleural Mesothelioma (MPM)

United States
Henan Cancer Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

China

Search clinical trials for: CAR-T ineligible

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations